Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | +40.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.13 | N/A | +40.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about their product development efforts. They are focused on operational efficiency and future growth opportunities.
Management highlighted ongoing efforts to advance their product pipeline.
They emphasized the importance of maintaining operational efficiency during this period.
There was a focus on future opportunities despite current challenges.
Soleno Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 3.5% in response, likely due to the lack of revenue information and forward guidance. Investors may be concerned about the company's future performance without clearer direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BLOOM ENERGY CORP Class A
May 11, 2020